Introduction

Histone Methylation

Human nucleosome particle, pbd code: 5y0c

Histone proteins aid in the packing of DNA for the purpose of compacting the genome in the nucleus of the cell and regulating physical accessibility of genes for transcription. The protein itself is an octamer of core proteins H2a, H2b, H3, and H4, which organize into two heterodimers; H1 and H5 act as linker proteins. About 145-157 base pairs wind around a histone heterodimer core. ^[1] Modifications to histone core proteins can affect the accessibility of transcription factors in the genome, either promoting or inhibiting transcription. Some of these modifications include methylation/demethylation, acetylation/deacetylation, and ubiquitination/deubiquitination. ^[2]

Specifically, histone methylation is associated with gene activation. ^[3] Many domain families fall under the histone methylase family, one of these enzymes being the family, which can target H3, H4, or H2a. Sites known for gene activation are Lysine-4, Lys-36, and Lys-79 on H3; whereas, methylation at Lys-9 and Lys- 27 on H3 and Lys-20 on H4 are known for gene inactivation.^[4] Typically, methylation of some of these sites are always present on both active and inactive genes, extra methylations required for activity; specifics of this characteristic depend on site and species of organism. ^[5] Some tumor related genes such as p53 are site specifically methylated to promote biological function ^[4], whereas hypomethylation of CpG is linked to tumor genesis. ^[2] A particular enzyme in the SET7 domain family is lysine methyltransferase, which acts on the histone by adding a methyl group to Lys4 on H3; the addition results in promotion of gene unwinding and gene transcription. ^[5], ^[3]

Lysine Methyltransferase (KMT) Structure

The structure of human histone methyltransferase SET7/9 was crystallized using x-ray diffraction at 1.75Å in its product form ^[5]. SET7/9 was crystallized with its cofactor was in its unmethylated form, S-adenosyl-Lhomocysteine (SAH), and with its product, a ten residue peptide with a methylated lysine at residue 4.

Overall Secondary Structure

Due to the composition of its secondary structure, KMT is an alpha-beta protein ^[5]. The helical composition includes 3 , with two residing in the SET domain and one in the C-terminal domain. The alpha helices in the SET domain are two turns while the C-terminal helix is by far the largest with 4 turns. There are also 2 in the SET domain which are each one turn. There are 21 total which reside in the N-terminal domain and the SET domain. The beta strands are primarily anti-parallel and multiple antiparallel strands are connected by Type 1 and Type 2 .

The Active Site

The active site and binding pocket of KMT contain residues and shape that optimize catalytic function and stability. First, the lysine of the histone enters the active site via the comprised of Tyr335 and Tyr337. Feeding the histone into the active site is initially difficult; however, once in the active site, the alkyl part of the histone chain is stabilized by the , and polar residues are stabilized by hydrogen bonding interactions on the surface. The Tyr335 and Tyr337 are also essential for stabilization of histone chain via hydrogen bonding. The itself contains the cofactor S-adenosyl methionine (SAM) which donates the methyl group in the reaction. ^[5] In the active site scene, the structures depict the post-reaction result, where the Lys has been methylated and SAM has been converted to S-adenosyl homocysteine (SAH).

Figure 2. KMT Mechanism

The reaction is catalyzed by Tyr305, Tyr245, carbonyl oxygens of the main chain in residues Ala295 and Ser290. Tyr305 and the carbonyl oxygens of Ala295 and Set 290 coordinate with a water molecule to in turn coordinate with one of the hydrogens off the nitrogen of the lysine, while oxygen of Tyr245 pulls on the other hydrogen of the nitrogen. Both of these actions allow nitrogen to become more nucleophilic and attack the carbon of the methyl group on the SAM, which is attached to a positively charged sulfur. The methyl group is then transferred and charge on the sulfur is resolvedl; SAM has been converted to SAH. ^[5]

The C-Terminal Domain

The C-terminal domain of lysine methyltransferase is very important for the catalytic activity of the enzyme. The structures of the serve the role of stabilizing the structures in the in the correct orientation for a reaction in the active site.^[5] Hydrophobic interactions in the C-terminal domain are mainly responsible for stabilizing the access channel for the lysine methylation site on histone H3. Residues 337-349 create a that stabilizes the orientation of two tyrosine residues Tyr 335 and Tyr337 that form the lysine access channel. Furthermore, the hydrophobic packing of alpha-helix 3 against beta-sheet 19, specifically , stabilize the orientation of the so that its methyl donating group is oriented toward the lysine access channel. The orientation of the SAM cofactor is further stabilized with its hydrophobic interactions with C-terminal domain residues . ^[5]

The N-terminal Domain

Figure 1. Clustal alignment of N-terminals

The N-terminal domain of SET7 is notably far from the active site and has not been shown to be involved in enzyme activity or participate in substrate binding. ^[6] With deletion of the N-terminal domain, studies have shown this modification does not affect SET7 activity. ^[5] Though not essential for catalytic activity, the N-terminal domain by interact with other small molecules or proteins to act as an allosteric regulator region to the C-terminal domain. ^[6]

Inhibitors

Figure 3. Sinefungin

Sinefungin is a potent methyltransferase inhibitor. It is a structural analog of S-adenosylmethionine that is more stable due to the ability to create two additional hydrogen bonds to its amine group in the active site. It has been used experimentally to inhibit the SET 7/9 protein on peritoneal fibrosis in mice and in human peritoneal mesothelial cells. ^[7] Studies found that sinefungin suppressed the cell accumulation and thickening in methylglyoxal peritoneal fibrosis. ^[8]